Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

• Status: Terminated
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Panobinostat is a drug that may slow down the growth of cancer cells or kill cancer cells by blocking certain enzymes. Panobinostat has shown effects against cancer in laboratory studies. However, it is not known if it will show the same activity in humans. Panobinostat has been given to participants with various types of cancers, including DLBCL, in previous research studies. In this study panobinostat will be given with the the antibody rituximab, which is FDA approved to be given with chemotherapy in DLBCL.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborators: Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute
• Treatments: Panobinostat; Rituximab

Criteria

Inclusion Criteria:

• Relapsed or refractory DLBCL

• More than 1 line of prior chemotherapy

Exclusion Criteria:

• Currently receiving anticancer therapy or investigational agents

• Major surgery within last 4 weeks

• Known leptomeningeal or brain metastases

• Known HIV infection

• Uncontrolled fungal, bacterial, viral or other infection

• History of another malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for at least 3 years

• Hepatitis B or C positive

• GI disease

• Pregnant or breastfeeding

• Prior treatment with an HDAC inhibitor including valproic acid